Blood Pressure Control in ESH Excellence Centres

Blood Pressure Clinical Trial

— BP-CON  

Official title:

Study of the European Society of Hypertension on Blood Pressure Control in ESH Excellence Centres

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04295434
• Other study ID #: BP-CON-ESH
• Status: Recruiting
• Start date: October 1, 2018
• Est. completion date: March 1, 2021

Study information

• Verified date: March 2020
• Source: Clinical Hospital Centre Zagreb
• Contact: Bojan Jelakovic, MD, PhD
• Phone: 00385959030751
• Email: jelakovicbojan[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In the BP-CON-ESH study we are going to include and analyze treated hypertensive patients seen consecutively by the ESH Excellence Centres. Blood pressure will be measured as usually done in the office, but care will be adopted to make measurements highly standardized in all Centres. The primary goals will be to determine the global, regional and country rates of hypertension control in Europe. Other goals will be to identify global and regional factors associated with blood pressure control in different European regions. The results obtained in the BP-CON-ESH project will be used to refine treatment strategies for improvement of blood pressure control and will serve as a basis for assessing future changes and trends in Europe.

Description:

The most important task of the European Society of Hypertension is to improve blood pressure treatment and increase blood pressure control, thus decreasing cardiovascular risk, premature cardiovascular and renal morbidity and mortality, with in addition a reduction of health-care costs. More than a decade ago, the European Society of Hypertension established a network of Excellence Centres. Those centres are leading institutions for the diagnosis and treatment of hypertension and thus are front runners of good clinical practice in hypertension management in their countries. An important task of the Excellence Centres is also to be active in research, particularly in projects conducted by the European Society of Hypertension. The ongoing BP-CON-ESH project on the rate of blood pressure control in hypertensive patients addresses the most elementary,but at the same timethe most important aspect in hypertension management, because the observed low rates of blood pressure control is the reason why hypertension is still today the leading cause of death worldwide.

In the BP-CON-ESH study we are going to include and analyze treated hypertensive patients seen consecutively by the ESH Excellence Centres. Blood pressure will be measured as usually done in the office, but care will be adopted to make measurements highly standardized in all Centres.

The primary goals will be to determine the global, regional and country rates of hypertension control in Europe. Other goals will be to identify global and regional factors associated with blood pressure control in different European regions. It is well known that the overall control of hypertension in Europe is still insufficient. However, the problem is not the same across Europe. Differences in healthcare systems exist among European countries, and in some countries government healthcare system only partially reimburse costs of antihypertensive therapy. There are also differences in gross national product, educational levels, salt consumption, prevalence of obesity and other aspects. These could cause dissimilarities in hypertension prevalence, achieved blood pressure control and cardiovascular mortality among European regions.

The results obtained in the BP-CON-ESH project will be used to refine treatment strategies for improvement of blood pressure control and will serve as a basis for assessing future changes and trends in Europe.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 3000
• Est. completion date: March 1, 2021
• Est. primary completion date: October 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Signed informed consent

Exclusion Criteria:

• Pregnancy and breastfeeding

• Terminal malignancy, reduced life expectancy (<6 months)

• Amputated limb

• Dementia

• Patients living in a nursing home

• Unsigned informed consent

Related Conditions & MeSH terms

• Blood Pressure
• Hypertension
• Lifestyle Risk Reduction
• White Coat Hypertension

Locations

Country	Name	City	State
Armenia	Center of Preventive Cardiology, Yerevan	Yerevan
Austria	Klinikum Wels-Grieskirchen	Wels
Belgium	Erasmus Hospital	Brussels
Belgium	CHU de Liège	Liège
Belgium	Ambroise Paré University Hospital	Mons
Bulgaria	University Hospital "St. Anna"	Sofia
Croatia	University hospital centre Zagreb	Zagreb	Grad Zagreb
Czechia	Charles University Medical School and University Hospital	Plzen
Czechia	Center for Hypertension, Charles University, Prague	Praha
Czechia	Institute for Clinical and Experimental Medicine (IKEM) and Thomayer Hospital, Prague	Praha
Estonia	Tallinn Hypertension Excellence Centre	Tallinn
Germany	Hypertension Center Berlin Charité	Berlin
Germany	Hypertoniezentrum Bonn	Bonn
Germany	Medizinische Hochschule Hannover	Hanover
Germany	Universitätskliniken des Saarlandes	Homburg
Germany	Hypertension Center Munich	Munich
Greece	Hypertension and Cardiovascular Prevention Clinic, 3rd Department of Medicine, Evangelismos Hospital	Athens
Greece	Hypertension Clinic, Cardiology Department, Asklepeion Hospital	Athens
Greece	Hypertension Clinic, Department of Cardiology, KAT General Hospital	Athens
Greece	Hypertension Clinic, University Hospital Laiko	Athens
Greece	University of Athens, Hippokration Hospital	Athens
Greece	University Hospital of Heraklion	Heraklion
Greece	Hypertension Center, Department of Nephrology, University Hospital of Ioannina	Ioánnina
Greece	Aristotle University of Thessaloniki, Papageorgiou General Hospital	Thessaloníki
Greece	Hypertension Center, Department of Nephrology, Hippokration Hospital, Aristotle University of Thessaloniki	Thessaloníki
Greece	Hypertension Outpatient Clinic, 1st Propedeutic Dept. of Internal Medicine, AHEPA Hospital	Thessaloníki
Israel	Assuta Ashdod University Hospital	Ashdod
Italy	Centre of Prevention and Treatment of Arterial Hypertension and Cardiovascular Risk Factors	Brescia
Italy	Ospedale Niguarda, Dip. De Gasperis e Università di Milano Bicocca	Milan
Italy	S. Luca Hospital, Istituto Auxologico Italiano	Milan
Italy	Napoli Hypertension Excellence Centre, Federico II Clinic Research Center for Hypertension and Related Conditions	Napoli
Italy	Excellence Centre of Hypertension, Department of Medical Sciences, University of Torino	Torino
Lebanon	American University Center, Hypertension/Vascular Medicine Division (Associated Centre)	Beirut
Lithuania	Kaunas Hypertension Excellence Centre	Kaunas
Netherlands	University Hospital Maastricht	Maastricht
Netherlands	Radboud University of Nijmegen Medical Center	Nijmegen
Poland	Department of Internal Medicine, Hypertension and Vascular Diseases, Warsaw Medical University	Warsaw
Portugal	Centro Hospitalar do Alto Ave, Minho University	Guimarães
Romania	Department of Cardiology and Internal Medicine, Emergency Clinical Hospital of Bucharest	Bucharest
Serbia	Centre for Hypertension of the Clinical Centre of Serbia	Belgrad
Spain	Hipertensión Clinic, Internal Medicine, Hospital Clinico, University of Barcelona	Barcelona
Spain	Hypertension Clinic, Nephrology Department, Reina Sofia University Hospital	Córdoba
Sweden	Danderyd University Hospital	Stockholm
Ukraine	National Scientific Center "The M.D. Strazhesko Institute of Cardiology"	Kyiv
United Kingdom	St. Bartholomew's Royal London School of Medicine & Dentistry	London
United Kingdom	The Pearl-Rose Clinic (Hypertension & Cardiovascular Risk), Hammersmith Hospital,	London

Sponsors (2)

Lead Sponsor	Collaborator
Clinical Hospital Centre Zagreb	European Society of Hypertension

Countries where clinical trial is conducted

Armenia,  Austria,  Belgium,  Bulgaria,  Croatia,  Czechia,  Estonia,  Germany,  Greece,  Israel,  Italy,  Lebanon,  Lithuania,  Netherlands,  Poland,  Portugal,  Romania,  Serbia,  Spain,  Sweden,  Ukraine,  United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Blood pressure control	Difference in blood pressure values between ESH Excellence Centres	Through study completion, an average of 1 year

External Links

•   ESH website with relevant informations on BP CON study